๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Immunotherapy of renal cell carcinoma

โœ Scribed by J. Edson Pontes; Robert P. Huben

Publisher
Springer-Verlag
Year
1984
Tongue
English
Weight
454 KB
Volume
2
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Current strategies for immunotherapy of
Current strategies for immunotherapy of renal cell carcinoma
โœ R. Heicappell; R. Ackermann ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 672 KB

Therapy for disseminated renal cell carcinoma (RCC) is a major problem, as RCC is almost completely resistant to standard therapeutic approaches such as chemotherapy or radiotherapy. The search for innovative strategies has led to new concepts based on the assumption that the cellular or soluble med

Role of immunotherapy in the treatment o
Role of immunotherapy in the treatment of bladder and renal cell carcinoma
โœ Nelson N. Stone; Michael J. Droller ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 533 KB

Much remains to be learned about the immune response in human neoplasia both in a phenomenological sense and in its therapeutic possibilities. Recruitment of immune response mechanisms in the defense against cancer development and in the cure of advanced disease, though theoretically sound, remains

Renal cell carcinoma with retroperitonea
Renal cell carcinoma with retroperitoneal lymph nodes : Impact on survival and benefits of immunotherapy
โœ Allan J. Pantuck; Amnon Zisman; Frederich Dorey; Debby H. Chao; Ken-ryu Han; Jon ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 130 KB

## Abstract ## BACKGROUND The current study was performed to determine the impact of the presence of retroperitoneal lymphadenopathy on the survival and response to immunotherapy of patients with metastatic renal cell carcinoma (RCC). ## METHODS A retrospective cohort study was performed with ou

Surgical resection of metastatic renal c
Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy
โœ Dr. Richard M. Shery; Harvey I. Pass; Steven A. Rosenberg; James C. Yang ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 473 KB ๐Ÿ‘ 2 views

Thirty-one patients with disseminated melanoma or renal cell cancer (RCC) who had a limited relapse or persistent disease after a partial or complete response to interleukin-2 (IL-z)-based immunotherapy underwent resection of progressing tumors or residual sites of disease. There were no surgery-rel